The roles of tertiary lymphoid structures in genitourinary cancers: molecular mechanisms, therapeutic strategies, and clinical applications

被引:0
作者
Yang, Jie [1 ]
Xiong, Xingyu [1 ]
Zheng, Weitao [1 ]
Xu, Hang [1 ]
Liao, Xinyang [1 ]
Wei, Qiang [1 ]
Yang, Lu [1 ]
机构
[1] Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
antitumor immunity; genitourinary cancer; immune checkpoint blockade; tertiary lymphoid structures; tumor immune microenvironment; RESISTANT PROSTATE-CANCER; RENAL-CELL CARCINOMA; PHASE-III TRIAL; B-CELLS; T-CELLS; UROTHELIAL CARCINOMA; PROGNOSTIC RELEVANCE; CHRONIC INFLAMMATION; IMMUNE CONTEXTURE; PLASMA-CELLS;
D O I
10.1097/JS9.0000000000001939
中图分类号
R61 [外科手术学];
学科分类号
摘要
The presence of tertiary lymphoid structures (TLSs) associated with distinct treatment efficacy and clinical prognosis has been identified in various cancer types. However, the mechanistic roles and clinical implications of TLSs in genitourinary (GU) cancers remain incompletely explored. Despite their potential role as predictive markers described in numerous studies, it is essential to comprehensively evaluate the characteristics of TLSs, including drivers of formation, structural foundation, cellular compositions, maturation stages, molecular features, and specific functionality to maximize their positive impacts on tumor-specific immunity. The unique contributions of these structures to cancer progression and biology have fueled interest in these structures as mediators of antitumor immunity. Emerging data are trying to explore the effects of therapeutic interventions targeting TLSs. Therefore, a better understanding of the molecular and phenotypic heterogeneity of TLSs may facilitate the development of TLSs-targeting therapeutic strategies to obtain optimal clinical benefits for GU cancers in the setting of immunotherapy. In this review, the authors focus on the phenotypic and functional heterogeneity of TLSs in cancer progression, current therapeutic interventions targeting TLSs and the clinical implications and therapeutic potential of TLSs in GU cancers.
引用
收藏
页码:5007 / 5021
页数:15
相关论文
共 164 条
  • [1] Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
    Allen, Elizabeth
    Jabouille, Arnaud
    Rivera, Lee B.
    Lodewijckx, Inge
    Missiaen, Rindert
    Steri, Veronica
    Feyen, Kevin
    Tawney, Jaime
    Hanahan, Douglas
    Michael, Iacovos P.
    Bergers, Gabriele
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (385)
  • [2] Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer
    An, Ye
    Sun, Jian-Xuan
    Xu, Meng-Yao
    Xu, Jin-Zhou
    Ma, Si-Yang
    Liu, Chen-Qian
    Liu, Zheng
    Wang, Shao-Gang
    Xia, Qi-Dong
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [3] Macrophage-Based Approaches for Cancer Immunotherapy
    Anderson, Nicholas R.
    Minutolo, Nicholas G.
    Gill, Saar
    Klichinsky, Michael
    [J]. CANCER RESEARCH, 2021, 81 (05) : 1201 - 1208
  • [4] Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches
    Antonioli, Luca
    Fornai, Matteo
    Pellegrini, Carolina
    Masi, Stefano
    Puxeddu, Ilaria
    Blandizzi, Corrado
    [J]. TRENDS IN MOLECULAR MEDICINE, 2020, 26 (11) : 1021 - 1033
  • [5] Immune checkpoint blockade in glioblastoma from tumor heterogeneity to personalized treatment
    Arrieta, Victor A.
    Dmello, Crismita
    McGrail, Daniel J.
    Brat, Daniel J.
    Lee-Chang, Catalina
    Heimberger, Amy B.
    Chand, Dhan
    Stupp, Roger
    Sonabend, Adam M.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (02)
  • [6] Lessons of Vascular Specialization From Secondary Lymphoid Organ Lymphatic Endothelial Cells
    Arroz-Madeira, Silvia
    Bekkhus, Tove
    Ulvmar, Maria H.
    Petrova, Tatiana V.
    [J]. CIRCULATION RESEARCH, 2023, 132 (09) : 1203 - 1225
  • [7] EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
    Babjuk, Marko
    Boehle, Andreas
    Burger, Maximilian
    Capoun, Otakar
    Cohen, Daniel
    Comperat, Eva M.
    Hernandez, Virginia
    Kaasinen, Eero
    Palou, Joan
    Roupret, Morgan
    van Rhijn, Bas W. G.
    Shariat, Shahrokh F.
    Soukup, Viktor
    Sylvester, Richard J.
    Zigeuner, Richard
    [J]. EUROPEAN UROLOGY, 2017, 71 (03) : 447 - 461
  • [8] Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
    Baxi, Shrujal
    Yang, Annie
    Gennarelli, Renee L.
    Khan, Niloufer
    Wang, Ziwei
    Boyce, Lindsay
    Korenstein, Deborah
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 360
  • [9] Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
    Beer, Tomasz M.
    Kwon, Eugene D.
    Drake, Charles G.
    Fizazi, Karim
    Logothetis, Christopher
    Gravis, Gwenaelle
    Ganju, Vinod
    Polikoff, Jonathan
    Saad, Fred
    Humanski, Piotr
    Piulats, Josep M.
    Gonzalez Mella, Pablo
    Ng, Siobhan S.
    Jaeger, Dirk
    Parnis, Francis X.
    Franke, Fabio A.
    Puente, Javier
    Carvajal, Roman
    Sengelov, Lisa
    McHenry, M. Brent
    Varma, Arvind
    van den Eertwegh, Alfonsus J.
    Gerritsen, Winald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) : 40 - +
  • [10] Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis
    Benzerdjeb, Nazim
    Dartigues, Peggy
    Kepenekian, Vahan
    Valmary-Degano, Severine
    Mery, Eliane
    Averous, Gerlinde
    Chevallier, Anne
    Laverriere, Marie-Helene
    Villa, Irene
    Harou, Olivier
    Salle, Francoise Galateau
    Villeneuve, Laurent
    Glehen, Olivier
    Isaac, Sylvie
    Hommell-Fontaine, Juliette
    Bibeau, Frederic
    [J]. VIRCHOWS ARCHIV, 2021, 479 (04) : 765 - 772